ClinicaliQ Trial Snapshot
- A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression — Recruiting • Phase II • Oncology • NCT07023627.
- Drug being tested: INCB123667, a novel therapeutic agent being evaluated for safety and efficacy in patients with platinum-resistant ovarian cancer (PROC) who have Cyclin E1 overexpression, representing a precision medicine approach targeting a specific molecular subtype.
- Patient eligibility overview: The trial focuses on patients with platinum-resistant ovarian cancer whose tumours demonstrate Cyclin E1 overexpression, a biomarker-driven selection strategy that identifies a potentially treatment-responsive patient population.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
Eligibility Snapshot
- : * Histological diagnosis of a high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. * Have platinum-resistant disease: * Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of a platinum-containing regimen. * Participants who have received 2 to 4 lines of platinum-based therapy must have progressed on or within 6 months after the last dose of platinum. * Willingness to undergo a pretreatment biopsy. Note: Tissue from a fresh pretreatment biopsy is preferred, however an archival sample is acceptable as long as the sample is no older than 5 years. * Received at least 1 and no more than 4 prior lines of systemic therapy following the initial diagnosis, after which single-agent therapy is considered an appropriate next therapeutic option. * Must have received bevacizumab unless there was a contraindication for its use. * If the tumor tests positive for FRα, participants must have received mirvetuximab soravtansine unless there is an exception for its use on medical grounds.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.